Skip to main content
Press release May 13, 2026

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Aligos Therapeutics, Inc. (ALGS)

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for
View original release